Keywords
Pediatrics
Child
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the characteristics of Kawasaki Disease (KD). Bibliographic review: KD is an acute febrile exanthematous pediatric disease, presenting mainly with lesions of systemic vasculitis. It has a worldwide distribution and is more common in Asian children. The diagnosis is purely clinical, as there are no adequately specific or sensitive tests available. The "classic" diagnosis involves five days of fever and four of the following five criteria: inflammation of the mucous membrane, rash, swelling of the hands and feet, bilateral conjunctivitis, and a solitary inflamed lymph node mass. Final considerations: Kawasaki disease is the most common medium vessel vasculitis in children. Its clinical course is divided into three phases: acute, subacute, convalescence. Single intravenous immunoglobulin (IVIG) at a dose of 2 g/kg body weight is the treatment of choice for KD, preferably on day 10, better if on day 7 of illness, but as soon as possible after diagnosis. If untreated, it is associated with the development of coronary artery aneurysms.
References
CHEN MR, et al. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children. Front Immunol, 2021; 12: 632890.
GALLIZZI R, et al. Kawasaki disease epidemic: pitfalls. Ital J Pediatr, 2020; 46(1): 121.
GONÇALVES LF, et al. Kawasaki and Covid-19 disease in children: a systematic review. Rev Assoc Med Bras (1992), 2020; 66(2): 136-142.
KANEKO K, et al. Our Evolving Understanding of Kawasaki Disease Pathogenesis: Role of the Gut Microbiota. Front Immunol, 2020; 11:1616.
LINDQUIST ME, HICAR MD. B Cells and Antibodies in Kawasaki Disease. Int J Mol Sci, 2019; 20(8): 1834.
MARCHESI A, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. Ital J Pediatr, 2018; 44(1): 102.
MARCHESI A, et al. Revised recommendations of the Italian Society of Pediatrics about the general management of Kawasaki disease. Ital J Pediatr, 2021; 47(1): 16.
MARRANI E, et al. How Should We Classify Kawasaki Disease?. Front Immunol, 2018; 9:2974.
MENIKOU S, et al. Kawasaki Disease: The Role of Immune Complexes Revisited. Front Immunol, 2019; 10:1156.
MORISHITA KA, GOLDAM RD. Kawasaki disease recognition and treatment. Can Fam Physician, 2020; 66(8): 577-579.
NIE H, et al. Five immune-gene-signatures participate in the development and pathogenesis of Kawasaki disease. Immun Inflamm Dis, 2021; 9(1): 157-166.
PADILLA LA, et al. Kawasaki Disease and Clinical Outcome Disparities Among Black Children. J Pediatr, 2021; 229: 54-60.
RIFE E, GEDALIA A. Kawasaki Disease: an Update. Curr Rheumatol Rep, 2020; 22(10): 75.
RIVAS MN, ARDITI M. Kawasaki disease: pathophysiology and insights from mouse models. Nat Rev Rheumatol, 2020; 16(7): 391-405.
ROWLEY AH. Is Kawasaki disease an infectious disorder? Int J Rheum Dis, 2018; 21(1): 20-25.
SANTOS BSD, et al. Clinical-Epidemiological relation between SARS-COV-2 and Kawasaki Disease: an integrative literature. Rev Paul Pediatr, 2021;39: e2020217.
SEKI M, MINAMI T. Kawasaki Disease: Pathology, Risks, and Management. Vasc Health Risk Manag, 2022; 18: 407-416.
SINGH S, et al. Diagnosis of Kawasaki disease. Int J Rheum Dis, 2018; 21(1):36-44.
TAN JMC, et al. Primary care approach to Kawasaki disease. Singapore Med J, 2021; 62(1): 2-7.
TREMOULET AH. Adjunctive therapies in Kawasaki disease. Int J Rheum Dis, 2018; 21(1): 76-79.
WANG L, et al. Kawasaki Disease- Management Strategies Given Symptoms Overlap to Covid-19: A Review. JNMA J Nepal Med Assoc, 2021; 59(236): 417-424.
ZHANG RL, et al. Current pharmacological intervention and development of targeting IVIG resistance in Kawasaki disease. Curr Opin Pharmacol, 2020; 54:72-81.